Autopsy report · NCT02710396

Genetic Predictors of Benefit to Pembrolizumab

“Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 4 years 9 months before it stopped.
• 19 participants enrolled.
• Results were posted on the registry 2 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Columbia University

Sponsor type

University, hospital or other

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Pembrolizumab; Carboplatin; Nab-paclitaxel; Pemetrexed

Participants

19

Sites

2

Countries

United States

Trials that died the same way

• Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
  “One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab + abemaciclib study arm is removed due to toxicity seen in other trials.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.